AstraZeneca's Brilinta can be given for more than one year, says US FDA
4th Sep 2015 07:05
(ShareCast News) - AstraZeneca has won an extension to US regulatory approval for its star blood thinning drug Brilinta to allow it to be given to patients for more than one year after a first heart attack. The new 60mg tablet, which has been approved by the Food and Drug Administration (FDA) for th
Read moreBroker tips: RBS, ARM Holdings, Astrazeneca
2nd Sep 2015 13:17
(ShareCast News) - Societe Generale upgraded Royal Bank of Scotland to 'hold' from 'sell' with an unchanged price target of 330p. It said the long-term view for RBS is attractive, namely to become a UK-focused retail and commercial bank. SocGen said the de-risking of the balance sheet has really ta
Read moreBroker tips: RBS, ARM Holdings, Astrazeneca
2nd Sep 2015 13:17
(ShareCast News) - Societe Generale upgraded Royal Bank of Scotland to 'hold' from 'sell' with an unchanged price target of 330p. It said the long-term view for RBS is attractive, namely to become a UK-focused retail and commercial bank. SocGen said the de-risking of the balance sheet has really ta
Read moreBroker tips: RBS, ARM Holdings, Astrazeneca
2nd Sep 2015 13:17
(ShareCast News) - Societe Generale upgraded Royal Bank of Scotland to 'hold' from 'sell' with an unchanged price target of 330p. It said the long-term view for RBS is attractive, namely to become a UK-focused retail and commercial bank. SocGen said the de-risking of the balance sheet has really ta
Read moreFTSE 100 movers: Ashtead jumps on strong interims; Glencore, BP in the red
2nd Sep 2015 13:16
(ShareCast News) - London's FTSE 100 was up 1% to 6,116 at 1423 BST in a choppy session as stocks rebounded from weakness on Tuesday. Industrial equipment rental firm Ashtead was the standout gainer after it posted better-than-expected first quarter pre-tax profits of £155m, up 23%, driven by solid
Read moreAstraZeneca lifted by HSBC upgrade to 'buy'
2nd Sep 2015 09:26
(ShareCast News) - Pharmaceuticals giant AstraZeneca got a boost after HSBC upgraded the stock to 'buy' from 'hold' on share price weakness and ahead of oncology news flow. The bank noted that AZN's shares have fallen 8% since the beginning of August and 16% since the year's highs in April. It attri
Read moreAstraZeneca and Valeant to partner up on psoriasis drug brodalumab
1st Sep 2015 07:46
(ShareCast News) - AstraZeneca has entered into a collaboration agreement with Valeant Pharmaceuticals International under which it will grant an exclusive licence for Valeant to develop and commercialise psoriasis drug brodalumab. Under the terms of the agreement, Valeant will make an upfront payme
Read moreAstraZeneca poaches Roche executive for chief medical officer role
24th Aug 2015 07:32
(ShareCast News) - AstraZeneca has hired an executive from Roche subsidiary Genentech to join as executive vice president of global medicines development and chief medical officer. The pharmaceutical company said in a release Sean Bohen would join from 15 September. Bohen will be in charge of Astra
Read moreAstraZeneca to pay Inovio up to $700m for cancer vaccine
10th Aug 2015 11:48
(ShareCast News) - AstraZeneca has entered into an agreement to buy the rights to an experimental cancer drug from Inovio Pharmaceuticals for up to $700m. Under the terms of the agreement, MedImmune - Astra's global biologics research and development arm - will acquire exclusive rights to Inovio's I
Read moreAstraZeneca signs $500m immuno-oncology deal with Heptares
6th Aug 2015 09:27
(ShareCast News) - Pharmaceutical giant AstraZeneca has signed a $500m deal to strengthen its position in the hot area of immuno-oncology with Japanese giant Sosei. The agreement with Sosei's subsidiary Heptares gives Astrazeneca the licence to acquire exclusive global rights to develop, manufacture
Read moreLondon close: Stocks end higher despite Fed decision
30th Jul 2015 18:00
(ShareCast News) - London share prices ended modestly higher despite the US Federal Reserve's decision to leave the door open to possible interest rate increases in September which, it must be pointed out, might add to the pressure on the Bank of England to also make a move soon. The Footsie ended t
Read moreFTSE 100 movers: Shell rallies on better-than-expected earnings, but Centrica drops after announcing job cuts
30th Jul 2015 15:56
(ShareCast News) - London's top-flight index was up 0.6% at 6,670 by 15:41 BST, as investors waded through a raft of earnings reports. Royal Dutch Shell and BG Group were both sharply higher after Shell's second-quarter results beat expectations. The Anglo-Dutch oil major posted adjusted profits of
Read moreLondon midday: Heavyweight corporate earnings lift FTSE 100
30th Jul 2015 12:37
(ShareCast News) - London share prices remained mostly in positive territory by midday on Thursday, as strong corporate results from heavyweights in various sectors, notably Shell, RBS and Astrazeneca, combined with a stronger oil price. At 12:15 the FTSE was up 0.79% to 6,683.11, almost recapturing
Read moreAstraZeneca's second-quarter earnings beat expectations; lifts sales guidance
30th Jul 2015 08:12
(ShareCast News) - AstraZeneca's second-quarter earnings beat expectations as generic competition and the effects of a stronger US dollar were offset by the spinning off of assets and a good performance from the company's Brillinta drug. The pharmaceuticals giant posted core operating profit of $1.8
Read moreThursday preview: Busy day of earnings await with flood of FTSE 350 interims
29th Jul 2015 15:48
(ShareCast News) - Investors will on Thursday be snowed under with earnings from a batch of FTSE 350 companies. Astrazeneca, Weir Group and Royal Dutch Shell will be among those reporting. Shell will be hoping to outperform BP in its second quarter results. BP on Tuesday reported a 64% drop in quar
Read more